Picture Consultech GmbH Secure Funding with RnD Grants v7 650x100px
Organisation › Details

Forbion Capital Partners (NL)

Forbion is a dedicated life sciences venture capital firm with offices in The Netherlands, Germany and Boston. Forbion invests in life sciences companies that are active in the (bio-) pharmaceutical space. Forbion manages €3 billion across multiple fund strategies that cover all stages of (bio-) pharmaceutical drug development. Forbion’s current team consists of over 30 life sciences investment professionals that have built an impressive performance track record since the late nineties with investments in over 95 companies across 8 funds. Forbion’s record of sourcing, building and guiding life sciences companies has resulted in many breakthrough therapies and valuable exits. Recent portfolio company successes include Inversago, Vectiv Bio, Versanis, Gyroscope, NewAmsterdam Pharma (NASDAQ: NAMS), Engene (NASDAQ: ENGN), and Replimune (NASDAQ: REPL). Besides financial objectives, Forbion selects investments that will positively affect the health and well-being of patients. The firm is a signatory to the United Nations Principles for Responsible Investment. Forbion operates a joint venture with BGV, the manager of seed and early-stage funds, especially focused on Benelux and Germany. *


Period Start 2006-12-01 splitoff
  Group Forbion (Group)
  Predecessor ABN AMRO Capital Life Sciences
Products Industry venture capital
  Industry 2 LIFE SCIENCES
Persons Person Slootweg, Sander (Forbion Capital Partners 20111 Managing Partner before ABN AMRO Capital)
  Person 2 Kersten, Dirk (Forbion 201810– General Partner before Inkef Capital + Gilde Healthcare)
Region Region Naarden
  Country Netherlands
  Street 2-35 Gooimeer
  City 1411 DC Naarden
  Tel +31-35-699-3000
    Address record changed: 2020-12-02
Basic data Employees B: 11 to 50 (2024-01-09)
  Currency EUR
  Annual sales 3,000,000,000 (capital under management (2024) 2024-01-09)
    * Document for »About Section«: Forbion Capital Partners. (1/9/24). "Press Release: Forbion Portfolio Company Aiolos Bio, Inc. (Aiolos) to Be Acquired by GSK for up to $1.4 Billion".
Record changed: 2024-07-04


Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Forbion (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x300px

» top